Drugs / Levulan Kerastick
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04552990 | Sep 2020 → Apr 2025 | nodular basal cell carcinoma, superficial multifocal basal cell carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levulan Kerastick | “jet-injection (AirGent2.0) of ALA (Levulan Kerastick)” NCT04552990 ↗ |
| Known as | ALA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04552990 ↗ |
| Route | Other | “The Basal Cell Carcinoma/BCC tumor and a 5 mm margin will be injected with a grid of 80 microliters of 20% ALA” NCT04552990 ↗ |